Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

PNC Financial Services

Sabra Health Care

AT&T

24/7 Insights With the S&P 500 up 15% year-to-date, a correction could be coming in the third quarter.

Deutsche Bank Has 4 Sizzling ‘Fresh Money' Dividend Stock Picks for Q3

Merck (MRK) reachead $126.04 at the closing of the latest trading day, reflecting a +0.21% change compared to its last close.

Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know

Cigna

Medtronic

Toll Brothers

Cigna, Merck, Toll Brothers, Medtronic could see shares gain after proving their earnings growth remains strong.

4 Cheap Stocks to Buy Ahead of Earnings

Chevron

Newmont Mining

Investing in undervalued blue-chip stocks might be the safe harbor your portfolio needs at this time. In the past year, we've seen blue-chip stocks play second fiddle to tech stocks.

3 Undervalued Blue-Chip Stocks Ready for a Big Comeback

Elanco Animal Health Inc

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the completion of its acquisition of the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN). The completion of this acquisition bolsters Merck Animal Health's position in the aqua industry with a comprehensive approach to promote fish health, welfare and sustainability in aquacultur.

Merck Animal Health Completes Acquisition of Elanco's Aqua Business

Transaction concentrates Elanco's focus on significant value creation opportunities and accelerates deleveraging progress GREENFIELD, Ind. , July 9, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today it has completed the divestiture of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash, with approximately $1.05-$1.1 billion in net proceeds available for debt paydown in the third quarter of 2024.

Elanco Completes Sale of Aqua Business

Amgen

Cardinal Health

Fiserv Inc

Globe Life Inc

JPMorgan Chase & Co

ONEOK

Omnicom Group

Amplify Blackswan Growth & Treasury Core ETF

Innovator Equity Defined Protection ETF - 2 Yr to July 2025

Vulcan Materials

Exxon Mobil

You don't get upset for having homeowner's insurance but your house doesn't burn down. The same principle should apply to investors who insure their stock portfolios against a crash.

‘Crash proof' your portfolio with these 10 stocks and 3 ETFs

Lockheed Martin

Altria

Rio Tinto plc Sponsored

Starbucks

An investor is unlikely to beat inflation by simply holding funds in a bank account. In such a scenario, there will be continued loss of purchasing power due to inflation increasing faster than average interest rates.

Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation

Merck offers strong forward earnings growth trends and a compelling current valuation, making it a GARP play with a high yield. The health care sector trades at an 18.9 forward earnings multiple, below that of the broader market. Merck's strong quarterly results, focus on new launches, and solid outlook make it a buy with the potential for double-digit growth in the coming years.

Merck: Among The Best Health Care GARP Plays Today

Comcast

Dominion Energy

Home Depot

Coca-Cola

Procter & Gamble

24/7 Insights Quality dividend stocks outperform non-dividend stocks for shareholders.

Buy These 7 Dividend Stocks and Hold Forever

Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.

Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

REDWOOD CITY, Calif.--(BUSINESS WIRE)--N-Power Medicine collaborates with Merck to expand oncologist and patient access to clinical trials.

N-Power Medicine Collaborates with Merck to Expand Oncologist and Patient Access to Clinical Trials

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Orion Corporation (“Orion”) today announced that notice has been provided of the mutual exercise of an option to convert the companies' ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for Merck. “We are pleased with the progress made to.

Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30.

Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30

Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.

Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe

Vale S.A.

In a portfolio, it's generally growth stocks that grab the limelight. Being high-beta stocks, the price action keeps investors on the edge.

7 Quiet Blue-Chip Stocks on the Verge of a Big Breakout Rally

Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.

Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH).

Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)

Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Bioreactors Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Fabrication Material, Type of Bioprocess, Type of Biologic, and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering.

Global Bioreactors Market Forecast Report 2024-2035 with Key Players Profiles of Applikon Biotechnology, Bionet, Cytiva, Eppendorf, Merck, Sartorius, Solaris Biotech, Solida Biotech and LABAO

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--CDC'S ACIP Unanimously Recommends Merck's CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults.

CDC'S ACIP Unanimously Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults

News out of a Centers for Disease Control and Prevention meeting appeared to dim the commercial prospects of Merck's new pneumococcal vaccine.

Merck Stock Is Slipping. A CDC Committee Considers Pneumococcal Vaccines.

Merck stock tumbled under its 50-day moving average Thursday after the FDA rejected its Daiichi Sankyo-partnered cancer drug.

Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection

The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.

Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection

Amazon

American Express

Microsoft

Walmart

Three of the best Dow stocks are in bases with two breaking out, including newbie and emerging AI play Amazon.

These Are The Best Dow Jones Stocks Of 2024 Thus Far

The U.S. Food and Drug Administration declined to approve Merck and Japan-based Daiichi Sankyo's lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like "guided missiles".

News for Merck Stock (MRK)